Eris Lifesciences Limited
Financial trend (77/100) does the heavy lifting; momentum (51/100) is the drag.
Buy zoneEris Lifesciences Limited earns a Buy from StocksWizard, with a blended score of 69/100. On 32.4x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 21% below its 52-week high of ₹1,806.9 and 13% above the low of ₹1,264.22. Financial health scores 85/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹1,696.6 implies about 19% upside across 10 analysts. It clears 6 of 13 investability checks, with durability 71, valuation 64 and momentum 51 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,358.02.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-21.05% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy69Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 18.1%
- Fail: Low debt (D/E < 0.5): 0.61x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: 7%
- Pass: Earnings growing: 200%
- Pass: Net margin ≥ 10%: 19.9%
- Fail: Current ratio > 1.5: 0.74
- Pass: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.38
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter69.7%
- Institutions22.7%
- Public & other7.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (18.1%).
- Healthy profit margin (19.9%).
- Financially solid — Altman Z 4.38.
Opportunities
- Earnings growing (200% YoY).
- Trading in our value buy zone versus sector peers.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
About Eris Lifesciences Limited
Eris Lifesciences Limited manufactures and distributes branded pharmaceutical formulations across multiple therapeutic areas, including antidiabetes, cardiovascular, dermatology, neuroscience, gynecology, nephrology, and oncology treatments. The company operates in India and internationally, offering products in nutrition, central nervous system care, women's health, and vitamins/minerals/nutrients, along with patient care services.
Eris Lifesciences Limited — frequently asked questions
Is Eris Lifesciences Limited a buy, hold or sell?
StocksWizard currently rates Eris Lifesciences Limited (ERIS) a Buy, based on a blended score of 69/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Eris Lifesciences Limited's fair value?
Our blended DCF and relative-valuation model estimates Eris Lifesciences Limited's fair value at about ₹1,697.53, versus a current price of ₹1,426.5 — roughly 19% upside. On that basis the stock looks undervalued by 19%.
Is Eris Lifesciences Limited financially healthy?
Eris Lifesciences Limited scores 85/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Eris Lifesciences Limited's share price performed?
Eris Lifesciences Limited is up 8% over three months, and last traded at ₹1,426.5. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.